Vanguard Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$279M Buy
533,246
+39,060
+8% +$20M 0.17% 95
2026
Q2
$245M Buy
494,186
+52,009
+12% +$23M 0.17% 104
2026
Q1
$197M Buy
+442,177
New +$206M 0.17% 108

Other funds holding VRTX

Vanguard Asset Management's VRTX Position: Q3 2026 in Review

Vanguard Asset Management increased its Vertex Pharmaceuticals (VRTX) stake by 7.9% in Q3 2026, buying an estimated $20M and bringing the position to 533,246 shares worth $279M. The position accounts for 0.17% of the portfolio, ranked #95.

Vanguard Asset Management first reported a position in VRTX in Q1 2026 and has held it in 3 quarters since. 1,798 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Vanguard Asset Management held 533,246 shares of Vertex Pharmaceuticals worth $279M as of Q3 2026.
  • Vanguard Asset Management bought 39,060 Vertex Pharmaceuticals shares in Q3 2026, an estimated $20M.
  • Vertex Pharmaceuticals made up 0.17% of Vanguard Asset Management's portfolio in Q3 2026, its #95 holding.
  • Vanguard Asset Management first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 1,798 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Vanguard Asset Management's 13F filing for Q3 2026, filed 13 Nov 2026.